Premium
Bone morphogenetic protein 6—a possible new player in pathophysiology of heart failure
Author(s) -
Banach Joanna,
Gilewski Wojciech,
Słomka Artur,
Buszko Katarzyna,
Błażejewski Jan,
Karasek Danuta,
Rogowicz Daniel,
Żekanowska Ewa,
Sinkiewicz Wadyslaw
Publication year - 2016
Publication title -
clinical and experimental pharmacology and physiology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.752
H-Index - 103
eISSN - 1440-1681
pISSN - 0305-1870
DOI - 10.1111/1440-1681.12665
Subject(s) - medicine , exacerbation , heart failure , cardiology , bone morphogenetic protein 6 , pathophysiology , bone morphogenetic protein 7 , bone morphogenetic protein , biochemistry , chemistry , gene
Summary Derangement of bone morphogenetic protein ( BMP ) signalling was observed in cardiovascular disorders. The present study assesses the diagnostic and prognostic value of BMP 6 plasma concentration in chronic heart failure ( CHF ). 130 CHF patients and 32 controls participated in the study. BMP 6 plasma level was measured at baseline. During 12‐month follow‐up death and hospitalisation with CHF exacerbation were recorded. BMP 6 was significantly increased in CHF patients with highest concentration in most advanced disease. Individuals with pulmonary congestion or peripheral oedema had higher levels of BMP 6 than isovolemic patients. BMP 6 was not a predictor of all‐cause mortality or CHF hospitalisation. BMP 6 may be involved in pathophysiology of systolic CHF . BMP 6 plasma level is related to the disease severity and signs of exacerbation.